ABBV - AbbVie Inc.
I continue to cover AbbVie with a 'Buy' rating due to its R&D achievements. So, in the past 3 months, Decnupaz and Skinvive by Juvederm have received FDA approvals. Moreover, a week ago, AbbVie reported promising results from the Phase 3 CLL14 trial for the treatment of chronic lymphocytic leukemia patients.
In the most recent trading session, AbbVie (ABBV) closed at $216.49, indicating a -2.14% shift from the previous trading day.
NORTH CHICAGO, Ill., June 18, 2026 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.73 per share.
Income investors keep coming back to the same playbook in choppy markets: own businesses that have raised their payouts every single year, no matter what the economy is doing.
AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
AbbVie maintains strong momentum in immunology, with Skyrizi and Rinvoq offsetting Humira declines and driving double-digit revenue growth. I reaffirm a 'Strong Buy' rating, supported by expanding indications for Skyrizi in Crohn's Disease and Rinvoq in alopecia areata and vitiligo. Skyrizi's subcutaneous induction for Crohn's Disease, validated by phase 3 AFFIRM data, targets further market share and revenue acceleration.
For income investors weighing biopharma exposure, the dividend question on AbbVie (NYSE:ABBV | ABBV Price Prediction) just got a lot easier to answer.
AbbVie (NYSE:ABBV | ABBV Price Prediction) has quietly become one of healthcare's most underrated growth stories.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Explore how portfolio concentration and stock count set these healthcare ETFs apart, impacting risk and diversification for investors seeking sector exposure.
SKINVIVE by JUVÉDERM® is now the first and only hyaluronic acid injectable approved to reduce horizontal neck lines caused by "tech-neck.1" This is the second FDA-approved indication for SKINVIVE by JUVÉDERM®, which has been approved since 2023 to improve skin smoothness of the cheeks in adults.1 IRVINE, Calif., June 16, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the U.S. Food and Drug Administration (FDA) approval of SKINVIVE by JUVÉDERM® to reduce neck lines for the improvement of neck appearance in adults over the age of 21.1 With this approval, SKINVIVE by JUVÉDERM® is the first and only hyaluronic acid (HA) injectable indicated to reduce the appearance of neck wrinkles and help skin retain its natural moisture, leading to an improved neck appearance.1 Neck wrinkles may develop due to natural aging, sun damage, weight loss, or "tech-neck" caused by the head-down position used for phones, tablets, and books.1 SKINVIVE by JUVÉDERM® reduces neck lines formed by tech-neck by helping the skin retain its natural moisture, softness, and smoothness.1 Treatment with SKINVIVE by JUVÉDERM® is minimally invasive with little to no downtime and is administered using an ultrafine needle or cannula.
Two retirees walk into retirement with the same amount of money. One builds a portfolio that pays $120,000 a year but barely grows. The other settles for $65,000 a year and focuses on dividend growth. At first glance, the first retiree appears to have won. Twenty-five years later, the second retiree may have collected more... The Retiree Who Chose $65,000 Instead of $120,000 and Ended Up Richer
The iShares Core Dividend Growth ETF (NYSEARCA:DGRO) was built for investors who want a paycheck that gets bigger every year, not a yield chase. DGRO tracks the Morningstar US Dividend Growth Index, screening for companies with at least five consecutive years of dividend growth and payout ratios under 75%. The fund pays a roughly 2.2%... 64 Years of Raises: How DGRO Finds Companies That Never Cut Dividends
Now's the time to load up on these high-yielders.
AbbVie (ABBV) closed at $227.73 in the latest trading session, marking a +1.32% move from the prior day.
The company is expanding both approved and pipeline therapies. New indications could expand the market for existing drugs.
NORTH CHICAGO, Ill., June 12, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new Phase 3 data on a fixed-duration venetoclax-based combination at the European Hematology Association (EHA) 2026 Congress taking place June 11-14 in Stockholm, Sweden.
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new Phase 3 data on a fixed-duration venetoclax-based combination at the European Hematology Association
AbbVie Inc. is rated a 'Buy' on accelerating fundamentals, robust pipeline progress, and a macro backdrop favoring defensive growth. SKYRIZI and RINVOQ are projected to deliver ~$31.8 billion in FY2026E revenue, with neuroscience emerging as a second growth pillar targeting ~$12.6 billion. EPS is expected to surge ~43% to $14.26 in FY2026E, with FCF up 54% and net debt/EBITDA declining to 1.6x.
AbbVie (NYSE:ABBV | ABBV Price Prediction) at $224.95 sits at the center of a sharp bull-bear debate.